Clinical Trials in Kericho, Kenya
7 recruiting
Showing 1–9 of 9 trials
Recruiting
Phase 3
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
Sickle Cell DiseaseThalassemia
Novo Nordisk A/S480 enrolled105 locationsNCT06609226
Recruiting
Phase 2
Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis
Tuberculous Meningitis
National Institute of Allergy and Infectious Diseases (NIAID)330 enrolled18 locationsNCT05383742
Recruiting
Phase 1
Safety and Pharmacokinetics Study of PGT121.414.LS Alone and in Combination With VRC07-523LS in Infants Exposed to HIV-1
HIV-1
National Institute of Allergy and Infectious Diseases (NIAID)48 enrolled17 locationsNCT06517693
Recruiting
Protocol RV 583 Multinational Observational Cohort of HIV and Other Infections
HIV Infections
Henry M. Jackson Foundation for the Advancement of Military Medicine2,500 enrolled4 locationsNCT05147519
Recruiting
Phase 1Phase 2
Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission
HIV Infection
National Institute of Allergy and Infectious Diseases (NIAID)1,120 enrolled46 locationsNCT02140255
Recruiting
Phase 2
Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV
Mild Neurocognitive DisorderMajor Depressive DisorderHIV
National Institute of Allergy and Infectious Diseases (NIAID)186 enrolled41 locationsNCT06705478
Recruiting
Phase 2
Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis
Pulmonary Tuberculosis
National Institute of Allergy and Infectious Diseases (NIAID)315 enrolled29 locationsNCT06192160
Recruiting
Phase 2
A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease
Sickle Cell Disease
Forma Therapeutics, Inc.95 enrolled18 locationsNCT06198712
Recruiting
Phase 1
The DART DELIVER-02 Study
HIV (Human Immunodeficiency Virus)
University of North Carolina, Chapel Hill24 enrolled3 locationsNCT07217379